ETC
MRSN

Exchange Traded Concepts’s Mersana Therapeutics MRSN Stock Holding History

Exchange Traded Concepts’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,400
Closed -$122K – 1387
2024
Q4 		$122K Hold
3,400
– – ﹤0.01% 1112
2024
Q3 		$161K Buy
3,400
+1,663
+96% +$73.4K ﹤0.01% 1038
2024
Q2 		$87.3K Sell
1,737
-540
-24% -$39K ﹤0.01% 949
2024
Q1 		$255K Sell
2,277
-1,672
-42% -$166K 0.01% 855
2023
Q4 		$229K Buy
3,949
+1,001
+34% +$40.3K 0.01% 779
2023
Q3 		$93.6K Buy
2,948
+2,336
+382% +$111K ﹤0.01% 919
2023
Q2 		$50.3K Buy
+612
New +$89.5K ﹤0.01% 1056

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Exchange Traded Concepts's MRSN Position: Q1 2025 in Review

Exchange Traded Concepts sold out of Mersana Therapeutics (MRSN) in Q1 2025, closing a stake of 3,400 shares — an estimated $122K sold.

Exchange Traded Concepts first reported a position in MRSN in Q2 2023 and held it in 7 quarters. The position peaked at $255K in Q1 2024. 108 funds tracked by Wall St. Rank hold MRSN as of Q1 2025.

  • Exchange Traded Concepts reported no remaining Mersana Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Exchange Traded Concepts sold 3,400 Mersana Therapeutics shares in Q1 2025, an estimated $122K.
  • Exchange Traded Concepts first reported a position in Mersana Therapeutics in Q2 2023 and held it in 7 quarters.
  • Exchange Traded Concepts's Mersana Therapeutics position peaked at $255K in Q1 2024.
  • 108 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2025.

Based on Exchange Traded Concepts's 13F filing for Q1 2025, filed 17 Apr 2025.